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responsibility of InAbstract Wear debris-induced aseptic loosening is an inﬂammatory bone disorder, which compromises
the long-term success of total joint replacement. Despite the extensive research and great progress in
treating inﬂammation-induced osteolysis for inﬂammatory arthritis, no drug has been proven for
treatment/prevention of aseptic implant loosening. Also, there is very limited research on developing
effective drug delivery systems for this pathological condition. In this review, we will discuss different
therapeutic interventions and various delivery systems that have been developed for aseptic implant
loosening. To provide the prospective for the future research in this area, the biology of wear particles-
induced osteolysis, animal models developed for aseptic implant loosening and the potential challenges
the ﬁeld is facing are also presented in the discussion.
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Despite the great progress in treating rheumatoid arthritis and
osteoarthritis, total joint replacement surgery still remains the
ﬁnal treatment option in many cases to relieve pain and
restore joint function. There are almost 1.5 million total joint
replacement surgeries performed annually worldwide and the
number is expected to increase to 4 million annually by
20301,2. Although total joint replacement provides great
success, the prosthetic implants are not built to last forever.
The overall 10-year success rate for total joint replacement is
90% with close to 10% of patients requiring revision surgery,
which is more challenging and associated with a shorter
duration of implant survival as well as posing higher risks
for the patients. Aseptic loosening is the predominant factor
limiting the longevity of the prosthesis, accounting for over
75% of joint replacement failure3. Other causes include
infection (7%), recurrent dislocation (6%), periprosthetic
fracture (5%), and surgical error (3%)3,4.2. Wear debris and osteolysis
Wear debris, primarily generated from the prosthetic joint
articular surface, is widely recognized as the major cause of
aseptic loosening5. Wear debris can be generated from all
the components of the prosthesis (including polyethylene,
ceramic and metal) as well as bone cement6. The accumula-
tion of wear particles over time leads to inﬂammatory
reactions and subsequent osteolysis around the implant
surface7. Wear debris are primarily phagocytosed by macro-
phages, resulting in the secretion of proinﬂammatory cyto-
kines, including tumor necrosis factor-a (TNF-a),
interleukin-1b (IL-1b), interleukin-6 (IL-6), interleukin-8
(IL-8) and prostaglandin E2 (PGE2). These cytokines up-
regulate nuclear transcription factor nuclear factor kappa B
(NF-kB) and further ensues the proinﬂammatory cascade.
The cellular mediators act in autocrine and paracrine
fashions, leading to the differentiation, maturation and
activation of osteoclasts from the precursor cells of hemo-
poietic lineage8,9. They also inhibit osteoprogenitor cells,
thereby inhibiting/suppressing proliferation, differentiation
and function of osteoblasts, as well as inducing apoptosis of
osteoblast10–13. In addition to inﬂammatory mediators,
lysosomal enzymes and matrix metalloproteinases (e.g.,
stromelysins, gelatinase and collagenase) are released, and
directly act on bone, causing further resorption14. These
factors act in concert, eventually disturbing the normal
homeostatic balance between bone degradation and forma-
tion, resulting in periprosthetic osteolysis. Several excellent
reviews have been published detailing the biology of wear
particles induced aseptic implant loosening3,4,15.3. Aseptic implant loosening animal model
In order to study the etiology, prevention and treatment of
aseptic implant loosening, several animal models have been
developed. It would take a signiﬁcant amount of time to
actually simulate/mimic the clinical scenario and establish an
animal model with gradual debris production. Even for
modiﬁed rat model which had a running wheel for 2 h/dayfor 5 days a week, it took 6 months to generate cement debris
particles and synovial-like interface membrane with areas of
bone resorption16. Due to the prohibitive natural wear particle
generation time frame, many research groups have chosen to
artiﬁcially introducing wear particles, in order to focus on the
biology of wear debris-induced osteolysis.
3.1. Large animal models
Several large animal prosthetic implant models using rabbits,
sheep and dogs have been developed to mimic the clinical
condition of interaction between implant–bone interface and
long term studies of aseptic loosening17–20. For these models,
stable intramedullary prosthesis was implanted and particles
were administrated at the implantation site. Due to the large
size of the bones and joints, they have advantages of using
clinically relevant implants, which can be subjected to appro-
priate physiological loads. The cost and management issues,
however, prevent the wide use of large animals, especially for
screening studies to explore novel therapeutic interventions.
3.2. Small animal models
Developing small animal models is of particular interest,
owing to cost effectiveness and easy handling. Furthermore,
the mouse genome is known. The availability of genetically
manipulated variants and molecular methods makes murine
models advantageous in identifying underlying biological
mechanisms. Currently, there are three commonly used mouse
models for studying implant loosening.
3.2.1. Murine air pouch model
This model was established on the back of a mouse by
subcutaneously injecting sterilized air, followed by surgical
introduction of a section of calvaria from a syngeneic mouse
donor21,22. Polyethylene, poly(methyl methacrylate) or metal
particles were then injected into the pouch. Osteolysis was
shown in the calvaria within 10 days. The soft tissue reactions
can be easily captured using this model. Due to the lack of
blood supply, however, the implanted bone is necrotic, which
ignores the self-healing (bone formation) process.
3.2.2. Murine calvaria model
To overcome the aforementioned problem in the air pouch
model, murine calvaria model was developed. In this model,
particles can be applied directly to the top of the calvaria
after a midline sagittal incision23,24. A minimum invasive
method was recently developed to introduce the particles by
direct injection of the suspension of the particles to the top of
the calvaria25. The particles deposited would lead to profound
inﬂammation, osteoclast formation and bone resorption within
1 week.
The murine air pouch and calvaria models represent many
biological features of the wear debris-associated osteolysis.
Because of the short duration of model induction, they are the
most frequently used animal models in implant loosening
research. Their limitations, however, are also obvious. The
models do not have a prosthetic implant and the prosthesis/
medullar canal interaction is absent. Furthermore, the time
needed to develop the models is very short, which does not
reﬂect the chronic nature of the clinical condition. Evidently,
Ke Ren et al.78these limitations would preclude the applications of these
models in the study of biomechanical properties of implant
and the evaluations of long-term effectiveness/safety of novel
therapeutic interventions.
3.2.3. Murine prosthesis failure model
Researchers have tried to implant polymer or metal rods on
mouse distal femur or proximal tibia to evaluate wear debris
induced periprosthetic inﬂammation and osteolysis with a non-
weight bearing characteristics26–28. Yang et al. developed a
mouse model with stainless steel or titanium-alloy pin implanted
into the proximal tibia of mice followed by monthly intra-
articular particles injection26,29. At 12 weeks post-surgery, they
showed a signiﬁcant decrease in periprosthetic bone mineral
density and pull-out force for particle challenged groups. In this
model, particles were introduced at the time of surgery and
periodically thereafter via intra-articular injections. While it is a
signiﬁcant improvement from the calvaria model, the model does
not precisely simulate the clinical situation where wear particles
are generated continuously by constant wear and tear due to
joint movement. To address this challenge, Goodman’s
group30–32 further improved this model by subcutaneously
implanting an osmotic pump. A hollow rod was press ﬁt into
the distal femur and connected to the particle suspension-loaded
pump, which can continuously deliver particles at a constant rate
to the intramedullary cavity. Clearly, this model simulates the
clinical scenario than all the other models. The cost of the model
development (including the surgery implantation and the cost of
the osmotic pump), however, is prohibitive.
3.2.4. Rat models
The rat version of the subcutaneous air-pouch model has also
been developed33. Due to the relatively bigger body size,
however, most of the rat studies have focused on incorpora-
tion of prosthesis. Similar to mouse situation, there are also
two versions of the rat models with prosthesis: (1) A pin was
implanted to the distal femur or proximal tibia with periodic
particle injection34,35; (2) A pin was inserted into the femur
with continuous intramedullary infusion of particles using an
osmotic pump36–38.4. Treatment options
To date, there is no drug speciﬁcally approved for prevention
or inhibition of periprosthetic osteolysis. The improved under-
standing of the biological cascade of wear particle-induced
aseptic implant loosening has suggested two potential ther-
apeutic targets: modulate osteoclast formation/function and
inhibit periprosthetic inﬂammation. The established aseptic
implant loosening animal models provide in vivo tools for
evaluation of these treatment options.
4.1. Modulate osteoclast formation and function
4.1.1. Bisphosphonates
For wear particle-induced osteolysis, the effector cell type for
bone destruction is osteoclasts. Therefore, effective inhibition
of osteoclast function becomes a natural target for therapeutic
intervention. Bisphosphonates have been shown to inhibit
mature osteoclast function and induce apoptosis. They are
commonly used for treatment of metabolic bone diseases suchas osteoporosis, hypercalcemia and Paget’s disease39,40.
Numerous experiments have proved the signiﬁcant decrease
in osteolysis after treatment with bisphpsphonate41–44. For
example, Horowitz et al.45 demonstrated pamidronate was
effective in reducing particle mediated osteolysis in vitro.
Alendronate inhibited wear particle-induced osteolysis in
murine calvarial model24 as well as both canine20 and rat46
models with tibial implants. Despite the promising positive
data for treating particle-induced osteolysis in cell culture and
animal studies, there is no signiﬁcant powered, randomized,
controlled clinical trial that could prove this type of drug can
effectively treat aseptic loosening in patients/clinical settings.
Therefore, clinical evaluation of bisphosphonates for treat-
ment/prevention of particle-induced osteolysis in patients
represents an area for future/further studies.
4.1.2. Statin
Another class of osteoclast inhibitor is statins. As 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibi-
tors, statins target the mevalonate pathway of osteoclast,
which is of the same inhibition mechanism as bisphospho-
nates. von Knoch et al.47 showed simvastatin treatment
markedly decreased ultra-high-molecular-weight polyethylene
(UHMWPE) debris-induced osteolysis in murine calvarial
model. They also did a comparison between statin and
bisphosphonate. A single dose of the zoledronate decreased
UHMWPE particle-induced osteolysis in murine calvarial
model as effectively as daily treatment with simvastatin48.
4.1.3. RANK/RANKL signaling blockade
The central role of receptor activator of nuclear factor kappa
B ligand (RANKL) in osteoclastogenesis makes it an attrac-
tive therapeutic target49. The inﬂammation induced by wear
debris leads to an increased expression of RANKL, an
essential osteoclast differentiation factor. It stimulates osteo-
clastogenesis and bone resorption by binding to RANK on
osteoclast precursors and mature osteoclasts. Osteoprotegerin
(OPG) is a naturally occurring decoy receptor for RANKL,
which could inhibit RANK/RANKL binding50. OPG gene
therapy has successfully proved reduced wear-debris-induced
osteolysis in murine calvarial model51,52. In addition, AMG-162,
a human immunoglobulin monoclonal antibody with high
afﬁnity for human RANKL, showed an anti-resorptive effect
for osteoporosis in postmenopausal women in clinical trials53–55.
It remains to be seen whether this agent will be effective in the
treatment of osteolysis patients.
4.1.4. NF-kB signal pathway inhibitor
Because RANK signaling is transduced via NF-kB, inhibitors
of this signaling pathway are effective in treating osteolysis. A
NF-kB essential modulator (NEMO)-binding domain peptide
has been found to block the binding of IKK2 and IKK1 to
IKKg/NEMO, inhibit NF-kB activation and alleviate poly
(methyl methacrylate) (PMMA)-induced inﬂammatory and
osteolytic responses in murine calvaria model56. Meanwhile,
bortezomib (a proteasome inhibitor) and pyrrolidine dithio-
carbamate (an IkBa stabilizer) were proved to be effective in
inhibiting titanium particle-induced inﬂammation in vitro and
in vivo57,58. In addition, Ren et al.59 demonstrated erythromy-
cin (EM) treatment inhibited wear debris induced inﬂamma-
tion, osteoclastogenesis and bone degradation in mouse
Therapeutic intervention for wear debris-induced aseptic implant loosening 79osteolysis model. More importantly, they also proved oral EM
could reduce the inﬂammation of periprosthetic tissues and
aseptic loosening in patients60. The mechanism study sug-
gested that EM inhibited wear debris-induced osteoclastogen-
esis by modulation of murine macrophage NF-kB activity61.
4.2. Inhibition of periprosthetic inﬂammation
4.2.1. Anti-tumor necrosis factor alpha (TNF-a) therapy
As mentioned before, inﬂammatory cytokines play a vital role
in the development of osteolysis. Modulation of inﬂammatory
cytokines has been explored as a potential treatment for wear-
debris induced osteolysis. Etanercept, a decoy receptor of
TNF-a, inhibits cytokine production from particle stimulated
macrophages and bone resorption in a bone wafer pit assay62.
For in vivo evaluation, etanercept reduced bone resorption and
osteoclastogenesis in a murine model of titanium particle-
induced osteolysis24. TNF-a gene delivery also demonstrated
its anti-resorptive effect in murine calvaria model63. For
clinical evaluation of etanercept, a pilot study of 20 patients
with established periprosthetic osteolysis was reported64.
However, the data showed no signiﬁcant difference in the
progression of osteolysis between the etanercept and placebo-
treated groups using a volumetric three-dimensional compu-
terized tomography as an outcome measurement technique.
The reasons might be etanercept itself, insufﬁcient sample
size or due to non-sensitive evaluation method, thus further
studies are needed. Another anti-TNF-a drug, which has been
investigated, is pentoxifylline, a potent TNF-a secretion
inhibitor. Orally administered pentoxifylline reduced the
inﬂammatory response of isolated monocytes to wear debris
in healthy subjects, but has not been tested in osteolysis
patients65.
4.2.2. COX-2 inhibitor
PGE2 is a well-known pro-inﬂammatory mediator of aseptic
loosening. COX-2 is the principal cyclooxygenase (COX)
responsible for the production of PGE2
66. As anti-
inﬂammatory agents, COX-2 inhibitors are clinically used in
the treatment of arthritis. Studies showed celecoxib, a COX-2
inhibitor, suppressed wear-debris induced osteolysis in both
murine calvaria and rabbit prosthesis model23,67.
4.2.3. Anti-inﬂammatory cytokines (IL-10 and IL-4)
Unlike proinﬂammatory cytokines, there are some anti-
inﬂammatory cytokines which possess immuno-regulatory
and inhibitory properties68. Two of such anti-inﬂammatory
cytokines that have been widely studied as options for the
treatment of osteolysis are IL-4 and IL-10. In vitro data
showed IL-4 or IL-10 could inhibit expression of TNF-a and
IL-6 by monocyte/macrophage in response to titanium or
PMMA particles69,70. Another approach is gene delivery.
Researches showed gene delivery of IL-10 inhibited TNF-a
and IL-1b production and inhibited wear debris-induced
osteolysis in both murine calvaria and air pouch model71,72.
4.3. Miscellaneous
4.3.1. Bone formation promoter
Both bone formation by osteoblasts and bone resorption by
osteoclasts are responsible for bone homeostasis. Agents thatpromote bone formation could also be used for treating
aseptic implant loosening. Transforming growth factor beta
(TGF-b) stimulates osteoblast-like cell proliferation and also
regulates osteoclast migration and differentiation. Local
administration of TGF-b increased bone ingrowth in a rabbit
model73. Fibroblast growth factor-2 (FGF-2), a protein
produced by osteoblasts, modulates osteoblastic prolifera-
tion/differentiation, stimulates endosteal bone formation and
induces neovascularization74. Local infusion of FGF-2
increased net bone formation in the presence of polyethylene
particles in the rabbit tibia75. In addition, besides inhibiting
osteoclasts, statins markedly promoted bone formation and
net bone growth in UHMWPE particle-induced osteolysis in
murine calvarial model76.
4.3.2. Other factors responsible for bone resorption
Besides osteoclast itself, other factors are also required for
bone resorption. For example, V-ATPases are proton pumps
playing a vital role in bone resorption by mediating extra-
cellular acidiﬁcation of the resorption lacuna between bone
surface and osteoclast rufﬂed border plasma membrane77,78.
Qin et al.79 proved saliphenylhalamide, a new V-ATPase
inhibitor, attenuated wear particle-induced osteolysis in mur-
ine calvarial model. There are also reports about anti-
resorptive effects of cathepsin K inhibitors80,81, vitronectin
receptor antagonists82,83 and src tyrosine kinase inhibitors84,
but with no publication reporting their direct use in treatment
of wear-debris induced osteolysis. These drugs may be
explored in the future as therapeutic or preventative agents
for the treatment of wear particle-induced osteolysis.5. Drug delivery system for implant loosening
The systemic anti-inﬂammation or anti-osteolysis therapies
discussed in the last section have several limitations, which
include the necessity of high-dose, lack of efﬁcacy, systemic
side effects, and consequently poor patient compliance.
Apparently, these limitations can be partially attributed to
the lack of tissue speciﬁcity of these medications to the wear-
particle induced osteolysis sites. To address this issue, a few
drug delivery systems have been explored to provide the drug
candidates with tissue speciﬁcity to osteolysis lesion.
5.1. Polymer drug conjugate
As discussed above, EM represented an interesting drug
candidate for the prevention and treatment of periprosthetic
membrane inﬂammation. In order to deliver adequate levels of
EM to the periprosthetic inﬂammation site with sustained
pharmacological activity, Admira et al.85 developed a poly
(amidoamine) dendrimer (PAMAM)-EM conjugate. PAMAM
G4-OH was partially functionalized with amine groups on the
surface using amino-valeric acid and conjugated to EM
prodrug (EM-20-glutarate) through an ester bond. In vitro
macrophage culture data suggested that the dendrimer enabled
more drugs to be transported into cells, and the conjugate
released the drug at a reasonable time frame. However, there is
no in vivo evaluation for this PAMAM-EM conjugate.
Besides dendrimer, N-(2-hydroxypropyl)methacrylamide
(HPMA) copolymer has been used as a carrier for anti-
inﬂammatory drug dexmethasone (Dex). The linker between
Ke Ren et al.80the HPMA copolymer and Dex is a hydrazone bond, which is
acid cleavable. The in vitro drug-release studies showed that
the release of Dex is almost linear with a sustained release rate
of about 1% of the loaded drug per day at pH 586. By using
murine calvaria model, a single tail vein injection of P-Dex
attenuated osteolysis with the same therapeutic effect as daily
Dex treatment25. In addition, P-Dex was proved to be
primarily localized at the particle-induced inﬂammation site.
Therefore, the conjugation resulted in a sustained and targeted
therapeutic effect with potentially reduced systemic adverse
effects.
5.2. Polymer matrix based drug delivery system
Different from the prodrug approach described in Section 5.1,
controlled drug release at the osteolysis lesion can also be
realized by physically entrapping therapeutic agents in poly-
meric matrix materials. For example, ﬂuvastatin poly(lactic-
co-glycolic acid) (PLGA) microspheres were prepared using an
in-water drying method. In vitro study showed a gradual
release of ﬂuvastatin for more than 1 month. In vivo study
demonstrated a signiﬁcant amount of new bone formation
around the titanium implant in rat tibia and an increase in
bone strength, 4 weeks after transdermal injection to the
dorsum of rats87.
The reported PLGA microsphere is the only publication
using polymer matrix based drug delivery system for treating
aseptic implant loosening. Others have used polymer matrix
system to establish lipopolysaccharide (LPS)-induced implant
loosening model or treat LPS induced implant loosening. For
example, an injectable hyaluronan gel has been developed as a
LPS delivery vector to establish murine calavarial model88.
The gel could maintain ﬂuidity for up to 30 min after cross-
linker was added, and the injection was performed within this
window to the calvaria site. Compared with pure LPS, the gel-
delivery system produced a dramatic increase in inﬂammatory
soft tissue deep to the calvarial bone due to the controlled
release and localization of LPS to the injection site. If the same
gel system is developed loading with drug, it might have a
great potential for application to intra-articular injection
against inﬂammation or osteolysis. In addition, a biodegrad-
able gelatin–chitosan cationic hydrogel loading an antisense
oligonucleotide (ASO) targeting murine TNF-a was developed
to treat LPS induced osteolysis89. The transfection efﬁciency
of the hydrogel was much higher than lipofectamine 2000 and
chitosan. In vivo data showed the hydrogel was digested and
absorbed 2 months after implantation. Hydrogel delivered
ASO could effectively suppress TNF-a, M-CSF, RANKL, and
notably decreased osteoclastogenesis, thus inhibiting osteoly-
sis. In contrast, naked ASO itself had little suppression effects.
Since TNF-a also played a very important role in aseptic
implant loosening, the hydrogel might also be effective in
treating this disease.
5.3. Implant coating
Coating bisphosphonates to the surface of implant is a widely
used method to increase osseo-integration90,91. Besides sys-
temic/local administration or directly coating drugs to the
implant, there is also ongoing research using polymer coating
with sustained release effect. Schmidmaier et al. developed abiodegradable poly(D,L-lactide) coating of implants for con-
tinuous release of growth factors for simulating fracture
healing92. The coating was 14.8 mm on titanium wire surface
with a reduction of about 8% within 6 weeks in vitro. The
same group also developed a implant coating using poly(D,L-
lactide) incorporated with bisphosphonates to inhibit osteo-
clasts. There was a signiﬁcant decrease in osteoclast formation
and activity in the coated group93. The data also showed an
increased OPG concentration and a beneﬁcial effect on
osteoblast differentiation and protein synthesis94.
5.4. Gene therapy
Zhang et al.95 developed a cell-based OPG gene therapy. They
transduced mouse ﬁbroblast-like synoviocytes (FLS) with
AAV-OPG or AAV-LacZ in vitro, and then transfused the
cells into the failing knee prosthesis. The FLS localized in the
knee joint periprosthetic tissue and expressed target protein,
resulted in a successful therapeutic inﬂuence by decreasing
TRAPþ and CD68þ cells, inﬂammatory cytokines, as well as
reversing bone resorption. Compared with the in vivo local
gene transfer, the cell-based technique had a comparable OPG
level, but with decreased potential side effects such as vector-
mediated cytotoxicity and adverse immunological reactions.6. Challenges and prospective
6.1. The lack of early detection method and therapeutic
outcome evaluation criteria
For orthopedic implant loosening, the most difﬁcult challenge
is early diagnosis. Currently, physical examination and peri-
odically radiographic evaluation are the only clinically used
methodology in identifying implant loosening96,97. However,
implant loosening is a silent disease with no clinical symptoms
and anatomical change at the early stage. Present radiographic
evaluation standards provide very limited information and
normally underestimate the degree of bone loss6,98. Although
three dimensional computed tomography, magnetic resonance
and positron emission tomography (PET) imaging have been
developed for measuring osteolysis99–101, there is still no
sensitive detection and clearly quantitative measurement cri-
teria of periprosthetic osteolysis at very early stage of the
disease development102. Therefore, the development of novel
early detection methodologies and the establishment of ther-
apeutic outcome evaluation criteria should be the main focus
of the ﬁeld.
Based on one of the pathological feature of inﬂammation
(leaky vasculature), a HPMA copolymer based early detection
system has been developed. The HPMA copolymer–IRDye
conjugate could identify sites of inﬂammation induced by the
wear debris at the early stage of implant loosening in murine
calvaria model25. Adaptation of this system for the use of
high-energy radioisotopes instead of optical imaging probes
might permit the development of imaging tools for human
application. To further increase the sensitivity of the detection
probe, active targeting moieties for inﬂammation could be
used. Because activated macrophages express folate recep-
tors103, folate-targeted imaging agents has been developed for
diagnose of adjuvant-induced arthritis in rats104,105. Because
of the important role of activated macrophages in the
Therapeutic intervention for wear debris-induced aseptic implant loosening 81development of peri-implant inﬂammation and subsequently
oseteolysis, this targeting moiety might have a potential
application in implant loosening as well.6.2. The lack of development in drug delivery system
Due to the well-established biology of wear-particle-induced
osteolysis, many therapeutic strategies have been explored as
treatment for implant loosening. Though no drug has been
speciﬁcally approved for the treatment of the disease, many
anti-inﬂammatory agents have been used off-label in clinical
management. As discussed in Section 5, most of these
medications do not have tissue speciﬁcity to the osteolysis
lesion. Therefore, after systemic administration of anti-
inﬂammation or anti-osteolysis drugs, their accessibility to
the osteolysis lesion relies solely upon vascular perfusion.
Because of the overall limited blood supply at the bone–
implant interface, high systemic drug dose is required to
achieve effective drug concentration at the site of loosening,
which often induces systemic adverse side effects. Meanwhile,
poor patient compliance is also a problem, considering the
development of implant loosening is a long and slow process,
which requires regular/frequent drug administration (e.g.,
daily). To overcome these limitations, there is a clear need
of developing better drug delivery system for the treatment of
this disease. As summarized in Section 5, however, the work in
this area was very limited.
As a chronic inﬂammatory skeletal disorder, aseptic implant
loosening shares many pathological similarities with arthritis,
including inﬂammation induced osteolysis, formation of peri-
prosthetic membrane/inﬂammation synovial membrane, acti-
vated monocytes/macrophages/ﬁbroblasts and elevated
inﬂammatory cytokines106,107. Many treatment therapies and
nanotechnologies that have been developed for treating arthritis
may also be applicable for aseptic implant loosening as well.6.2.1. ELVIS mechanism and systemic delivery
The inﬂammation process is characterized by a sequence of
pathophysical events, including vasculature restructuring,
inﬂammatory cell recruitment, destruction of the initiating
stimulus, removal and repair108. The enhanced vascular
fenestration allows small, colloidal drug delivery systems to
extravasate at the inﬂammation site and then be sequestered
by local inﬂammatory cells. This novel passive-targeting
mechanism has been validated in the treatment of several
inﬂammatory disease models and was coined as ELVIS
(extravasation through leaky vasculature and inﬂammatory
cell-mediated sequestration) mechanism109–112. The ﬁelds of
drug delivery and nanomedicine have matured over the years
with many delivery tools developed to accommodate a wide
range of therapeutic agents and to increase their therapeutic
index. Long circulating liposomes, macromolecular prodrugs,
nanoparticles, and micelles can all be explored to target the
osteo-inﬂammation site via ELVIS mechanism. Furthermore,
targeting ligands can also be introduced to the delivery system
to enable active targeting. Folate targeted therapies has been
developed for treatment of rheumatoid arthritis, allowing
decreased toxicity to normal tissues113,114. Other targeting
ligands may also be used, such as the E-selectin ligand
overexpressed on the surface of leukocytes115 and alpha vbeta 3 integrins expressed on angiogenic vascular endothelial
cells116,117.
6.2.2. Local delivery
Aseptic implant loosening is a local inﬂammatory disease. This
provides an opportunity for local treatment via intra-articular
route, resulting in a high local concentration with decreased
systemic exposure. However, rapid clearance from the joint
cavity could impair the effectiveness of this strategy and
require frequent administration. Furthermore, the technical
difﬁculty in intra-articular injection, the potential safety
concern and poor patient compliance limit its application.
Therefore, there is a need for the development of effective
local delivery systems with sustained therapeutic effect. For
such approach, delivery systems such as nanoparticles, lipo-
somes, microspheres or hydrogels may be considered for intra-
articular or transdermal delivery.
6.2.3. Delivery systems for combination therapy
Periprosthetic osteolysis involves a cascade of proinﬂam-
matory mediators, cell-signaling mechanisms and cellular
elements. They are complex and interrelated. Therefore,
concerns have been raised for the attempt of blocking only
one therapeutic target. For example, OPG treatment could
decrease bone loss, but not reduce inﬂammation. Elevated
levels of IL-1b and TNF-a are able to promote osteoclas-
togenesis even in the presence of very low RANKL levels118.
Based on this assessment, we believe the administration of
combination therapy, which would block multiple patholo-
gical pathways, would be efﬁcacious in term of clinical
management of peri-implant osteolysis. Apparently, such
therapeutic strategy would necessitate the development of
formulations that would delivery multiple therapeutic
agents simultaneously.7. Conclusion
Aseptic implant loosening is a major complication in total
joint replacement. Considerable effort has been invested in
understanding the biology and identiﬁcation of therapeutic
interventions for the disease. A thorough research of literature
has revealed, however, that the development of early diag-
nostic tools and drug delivery systems for the disease has been
very limited. Given the projected signiﬁcant increase of total
joint replacement procedure in the coming years and the fact
that wear particle-induced osteolysis is unavoidable; we
believe this is a ﬁeld of opportunity for pharmaceutical
scientists. As a vast arsenal of nanotechnology tools has been
developed during the last decade, we believe there is a lot that
we can contribute to improve the current clinical diagnosis
and therapeutic intervention of aseptic implant loosening.
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